Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD.

Abstract:

:The efficacy of posttransplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) in controlling GVHD has been previously reported. We aim to study the safety and efficacy of the use of dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning regimen allo-HSCT in 270 patients with hematological malignancies. Median follow-up was 12.7 months. Nineteen percent of patients received grafts from a matched related donor, 46% from 10/10 matched unrelated donors (MUD), 16% from 9/10 MUD and 19% from haploidentical donors. Graft failure rate was 9%. CMV and EBV reactivation rates were 58 and 64%. The cumulative incidence of grade II-IV and III-IV acute GVHD at day + 100 was 20.1% and 4.6%, respectively. The CI of moderate/severe chronic GVHD at 1 year was 12.4%. There were no differences in the incidence of GVHD according to donor type. One-year OS, RFS, NRM, CIR, and GVHD-free/RFS respectively were 65.2%, 56.9%, 22.7%, 20.3%, and 47.6%. Higher disease-risk index and worse Karnofsky performance status were significant factors for poor outcomes. In conclusion, the use of T-cell dual depletion with ATG and PTCy results in very low rates of acute and chronic GVHD and acceptable relapse rates and NRM.

journal_name

Bone Marrow Transplant

authors

Salas MQ,Prem S,Atenafu EG,Datt Law A,Lam W,Al-Shaibani Z,Loach D,Kim DDH,Michelis FV,Lipton JH,Kumar R,Mattsson J,Viswabandya A

doi

10.1038/s41409-020-0813-9

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

1773-1783

issue

9

eissn

0268-3369

issn

1476-5365

pii

10.1038/s41409-020-0813-9

journal_volume

55

pub_type

杂志文章
  • Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.

    abstract::Hematopoietic growth factors like G-CSF or GM-CSF have been shown to shorten the period of severe neutropenia after HD chemotherapy and autologous BMT, and are now widely used to mobilize hemopoietic stem cells into peripheral blood. In order to evaluate the possibility of delaying G-CSF administration after transplan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Faucher C,Le Corroller AG,Chabannon C,Novakovitch G,Manonni P,Moatti JP,Nouyrigat P,Maraninchi D,Blaise D

    更新日期:1996-04-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.

    abstract::To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituximab-augmented donor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.150

    authors: Hahn M,Böttcher S,Dietrich S,Hegenbart U,Rieger M,Stadtherr P,Bondong A,Schulz R,Ritgen M,Schmitt T,Tran TH,Görner M,Herth I,Luft T,Schönland S,Witzens-Harig M,Zenz T,Kneba M,Ho AD,Dreger P

    更新日期:2015-10-01 00:00:00

  • Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions.

    abstract::The indolent non-Hodgkin's lymphomas are theoretically curable through allogeneic haematopoietic stem cell transplantation (allo-HSCT). The applicability of standard conditioning allo-HSCT is, however, restricted by its toxicity. Recently, reduced-intensity conditioning regimens have demonstrated efficacy with signifi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703898

    authors: Ho AY,Devereux S,Mufti GJ,Pagliuca A

    更新日期:2003-04-01 00:00:00

  • Concentration of bone marrow progenitor cells by separation on a Percoll gradient using the Haemonetics model 30.

    abstract::To perform an optimal ex vivo bone marrow purge, it is necessary to concentrate the bone marrow progenitor cells and to eliminate both the red blood cells and the polymorphonuclear leucocytes. To achieve this goal which cannot be accomplished by using the Haemonetics model 30 alone, we used the Haemonetics model 30 an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Humblet Y,Lefebvre P,Jacques JL,Bosly A,Feyens AM,Sekhavat M,Agaliotis D,Symann M

    更新日期:1988-01-01 00:00:00

  • Evaluation of optimal survival of primitive progenitor cells (LTC-IC) from PBPC apheresis products after overnight storage.

    abstract::Optimal overnight (ON) storage of PBPC aphereses is becoming an increasingly important issue and different options for storing PBPC products exist. The survival of primitive progenitor cells is of major interest, as recent data suggest that these progenitors are not only important for long-term engraftment but also co...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702104

    authors: Petzer AL,Gunsilius E,Zech N,Clausen J,Hoflehner E,Nussbaumer W,Gastl G

    更新日期:2000-01-01 00:00:00

  • Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma.

    abstract::Repeated high-dose (HD) chemotherapy with peripheral blood stem cell (PBSC) transplantation is a new modality aimed at increasing both the dose and its intensity in the treatment of chemosensitive tumours. The aim of this study was to evaluate the tolerance, pharmacokinetics (PK) and pharmacodynamics (PD) of HD single...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702806

    authors: Vassal G,Tranchand B,Valteau-Couanet D,Mahé C,Couanet D,Schoeppfer C,Grill J,Kalifa C,Hill C,Ardiet C,Hartmann O

    更新日期:2001-03-01 00:00:00

  • Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group.

    abstract::Bone marrow transplantation recipients who were cytomegalovirus (CMV) seropositive and/or had a CMV seropositive donor were randomized for treatment with CMV hyperimmune plasma (n = 27) or no treatment at all (n = 27). The CMV hyperimmune plasma had neutralization titers greater than 250 and enzyme-linked immunosorben...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Ringdén O,Pihlstedt P,Volin L,Nikoskelainen J,Lönnqvist B,Ruutu P,Ruutu T,Toivanen A,Wahren B

    更新日期:1987-10-01 00:00:00

  • Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?

    abstract::The natural history of multiple myeloma (MM) was revolutionized by the introduction of haematopoietic stem cell transplantation to the treatment armamentarium of this disease. Defined subgroups of MM patients (such as the elderly or dialysis-dependent) have required an individualized approach in order to minimize the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705395

    authors: Bahlis NJ,Lazarus HM

    更新日期:2006-07-01 00:00:00

  • Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.

    abstract::There is substantial progress in preventing and treating cytomegalovirus (CMV) infections and CMV-related disease after allogeneic bone marrow transplantation. In CMV-seronegative recipients, use of CMV-seronegative blood products eliminates most CMV infections. Effective prophylaxis for CMV-seropositive recipients is...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Winston DJ,Gale RP

    更新日期:1991-07-01 00:00:00

  • Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD).

    abstract::Salivary gland dysfunction is frequently observed in patients suffering from acute (a) and chronic (c) GVHD. We studied the influence of GVHD on the function of major salivary glands in 20 patients with GVHD (cGVHD, 15; aGVHD, 5). A subjective evaluation of salivary function was performed, in which the score ranged fr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Nagler R,Marmary Y,Krausz Y,Chisin R,Markitziu A,Nagler A

    更新日期:1996-02-01 00:00:00

  • Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia.

    abstract::Antisense oligodeoxyribonucleotides (ODN) targeted against the breakpoint in BCR-ABL mRNA will specifically decrease BCR-ABL mRNA, provided cells are first permeabilised with streptolysin-O (SL-O). We used 18-mer chimeric methylphosphonodiester: phosphodiester linked (4-9-4) ODN complementary to 9 bases either side of...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701801

    authors: Clark RE,Grzybowski J,Broughton CM,Pender NT,Spiller DG,Brammer CG,Giles RV,Tidd DM

    更新日期:1999-06-01 00:00:00

  • Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy.

    abstract::Bone marrow transplant-associated thrombotic microangiopathy (BMT-TM) ranges in severity from a self-limiting to a fatal disorder. There is no specific therapy for this condition to date. We have previously described a simple clinical grading system (grade 0-4) for BMT-TM; patients with grade 3-4 BMT-TM do poorly. A p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zeigler ZR,Shadduck RK,Nath R,Andrews DF 3rd

    更新日期:1996-01-01 00:00:00

  • An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant.

    abstract::The purpose of the study was to assess the toxicity and efficacy of an oral, combination antiemetic regimen including granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA, USA) in the setting of highly emetogenic conditioning chemotherapy for stem cell transplantation. Antiemetic prophylaxis consi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700911

    authors: Frakes LA,Brehm TL,Kosty MP,Miller WE,McMillan RL,Mason J,Meisenberg BR

    更新日期:1997-09-01 00:00:00

  • Acute portal vein thrombosis after autologous stem cell transplantation.

    abstract::Three patients developed abdominal pain and abnormal liver enzymes without hyperbilirubinemia, early after autografting for lymphoma. Two had received conditioning therapy with busulfan, cyclophosphamide and continuous infusion etoposide; the other had received busulfan and melphalan. Doppler ultrasound in all cases d...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Grigg A,Gibson R,Bardy P,Szer J

    更新日期:1996-11-01 00:00:00

  • Transplantation of unrelated donor umbilical cord blood utilizing double-unit grafts for five teenagers with transfusion-dependent thalassemia.

    abstract::To augment graft cell dose, we evaluated the safety of the combined transplantation of two partially HLA-matched umbilical cord blood (UCB) units. Five patients with transfusion-dependent thalassemia, median age 11.1 years (range 10-13.1), received 2 UCB units after myeloablative conditioning. Cord blood units were a ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1705737

    authors: Jaing TH,Yang CP,Hung IJ,Chen SH,Sun CF,Chow R

    更新日期:2007-08-01 00:00:00

  • Combination antifungal therapy: what can and should we expect?

    abstract::Invasive fungal infections are associated with significant morbidity and mortality among immunocompromised patients. Recent advances in antifungal development have afforded us more pharmacologic compounds to choose from when managing these fungal infections. The role of combination antifungal therapy has been well est...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705687

    authors: Johnson MD,Perfect JR

    更新日期:2007-08-01 00:00:00

  • Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.

    abstract::A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Calderwood S,Doyle JJ,Hitzler JK,Saunders EF,Freedman MH

    更新日期:1996-07-01 00:00:00

  • Hematopoietic recovery from host progenitors with normal karyotype devoid of Philadelphia chromosome in a patient with CML after allogeneic BMT.

    abstract::A male patient with CML received a BMT from his sister and developed chronic GVHD. The host-origin normal karyotype (46,XY) was identified for the first time in the 60th month after BMT. Detection of Y-chromosome-specific DNA in BM and peripheral blood (PB) showed that all BM samples obtained 6 months from BMT were po...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Okamoto T,Kanamaru A,Wada H,Takemoto Y,Kakishita E,Hashimoto T,Furuyama J,Nagai K

    更新日期:1993-07-01 00:00:00

  • First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.

    abstract::Extragonadal germ cell tumors are classified according to the staging system of the International Germ Cell Cancer Collaborative Group (IGCCCG). The 5-year overall and disease-free survival rates for poor prognosis patients are 41 and 48%, respectively after standard-dose chemotherapy. We report the experience of the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704704

    authors: Rosti G,De Giorgi U,Wandt H,Lioure B,Leyvraz S,Kolbe K,Papiani G,Ballardini M,Kulekci A,Demirer T,Solid Tumours Working Party.

    更新日期:2004-12-01 00:00:00

  • Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

    abstract::We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.154

    authors: Chen J,Wang RX,Chen F,Sun AN,Qiu HY,Jin ZM,Tang XW,Han Y,Fu ZZ,He GS,Miao M,Ma X,Wu DP

    更新日期:2014-02-01 00:00:00

  • Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation.

    abstract::Acute inflammatory demyelinating polyneuropathy (AIDP) appeared in two patients following allogeneic bone marrow transplantation (BMT). In one transplanted patient (but not in the donor) T cells were sensitized against peripheral nervous system myelin. This could reflect a change in the T cell repertoire in a differen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Eliashiv S,Brenner T,Abramsky O,Shahin R,Agai E,Naparstek E,Steiner I

    更新日期:1991-10-01 00:00:00

  • Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.

    abstract::Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recover...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702819

    authors: Platzbecker U,Thiede C,Freiberg-Richter J,Röllig C,Helwig A,Schäkel U,Mohr B,Schaich M,Ehninger G,Bornhäuser M

    更新日期:2001-03-01 00:00:00

  • The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.

    abstract::We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underw...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.408

    authors: Hoppe BS,Moskowitz CH,Zhang Z,Maragulia JC,Rice RD,Reiner AS,Hamlin PA,Zelenetz AD,Yahalom J

    更新日期:2009-06-01 00:00:00

  • Measurement of reticulated platelets following peripheral blood progenitor cell and bone marrow transplantation: implications for marrow reconstitution and the use of thrombopoietin.

    abstract::Neutrophil and platelet engraftment times are significantly shorter in patients undergoing PBPCT compared with ABMT. The explanation for this is unclear. The reticulated platelet percentage (RP%) has been established as a measure of bone marrow platelet production. Using this measurement we have followed thrombopoiesi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Richards EM,Jestice HK,Mahendra P,Scott MA,Marcus RE,Baglin TP

    更新日期:1996-06-01 00:00:00

  • Cord blood stem cell transplantation for Diamond-Blackfan anemia.

    abstract::Bone marrow transplantation has been successfully employed in the treatment of Diamond-Blackfan anemia (DBA). Transplantation with bone marrow stem cells involves, however, considerable treatment-related toxicity, partially in the form of GVHD. Through the use of cord blood stem cells it may be possible to reduce the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700675

    authors: Vettenranta K,Saarinen UM

    更新日期:1997-03-01 00:00:00

  • Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.

    abstract::Human cytomegalovirus (CMV) is a major cause of death after transplantation. The frequency of pp65-specific T cells was examined in 38 HLA-A2+ stem cell recipients during the first year after transplantation. Patients were divided into four groups based on donor/recipient serostatus: d+/r+ (n=17), d+/r- (n=7), d-/r+ (...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1705585

    authors: Ganepola S,Gentilini C,Hilbers U,Lange T,Rieger K,Hofmann J,Maier M,Liebert UG,Niederwieser D,Engelmann E,Heilbronn R,Thiel E,Uharek L

    更新日期:2007-03-01 00:00:00

  • Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.

    abstract::Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions ad...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705751

    authors: Gurkan E,Patah PA,Saliba RM,Ramos CA,Anderson BS,Champlin R,de Lima M,Lichtiger B

    更新日期:2007-09-01 00:00:00

  • Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors.

    abstract::The role of ICU support in BMT patients is controversial. In an era of constrained resources, the use of prognostic factors predicting outcome may be helpful in identifying patients who are most likely (or unlikely) to benefit from this intervention. We attempted to define the survival of patients admitted to ICU foll...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701158

    authors: Jackson SR,Tweeddale MG,Barnett MJ,Spinelli JJ,Sutherland HJ,Reece DE,Klingemann HG,Nantel SH,Fung HC,Toze CL,Phillips GL,Shepherd JD

    更新日期:1998-04-01 00:00:00

  • The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.

    abstract::HA-1(H) is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1(H)-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705689

    authors: Torikai H,Akatsuka Y,Miyauchi H,Terakura S,Onizuka M,Tsujimura K,Miyamura K,Morishima Y,Kodera Y,Kuzushima K,Takahashi T

    更新日期:2007-07-01 00:00:00

  • Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.

    abstract::A retrospective comparison was carried out on adult patients receiving HLA-identical allogeneic haemopoietic stem cell transplants from siblings in Australia in 1996, comparing bone marrow with G-CSF-mobilised peripheral blood stem cells. A total of 131 transplant recipients from nine centres were included in this stu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1703088

    authors: Nivison-Smith I,Bradstock KF,Szer J,Durrant S,Dodds A,Hermann R,Schwarer AP,Gibson J,To LB,Arthur C,Australian Bone Marrow Transplant Cooperative Sutdy Group.

    更新日期:2001-07-01 00:00:00